VAXX News and Press, Vaxxinity Inc. From 12/03/21

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Vaxxinity (NASDAQ: VAXX) , a clinical-stage biotech, recently IPOed for a price lower than the previously announced range. In this Motley Fool Live video recorded on Nov. 15 , Motley Fool contributors Keith Speights and Brian Orelli discuss the prospects for the company's ex...

Friday’s COVID-related market selloff had a mixed impact on shares of recent IPOs – with lockdown-sensitive names like fat-removal firm AirSculpt Technologies (NASDAQ:AIRS) sinking, but biotechs like iSpecimen (NASDAQ:ISPC) and in-home fitness firms like Beachbody (NYSE:BODY) ra...

Vaxxinity (NASDAQ:VAXX) has closed its 6M-share IPO and has raised $85M in proceeds. BofA Securities, Jefferies and Evercore ISI acted as lead book-runners. Underwriters purchased an additional 537,711 shares. Vaxxinity priced its shares at $13. They closed today at $15.32. For further deta...

DALLAS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the closing of its initial public offering of 6,000,000 shares of class A common stock at a public o...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rivian (NASDAQ: RIVN ) stock is taking off on Tuesday and we’re diving into all the latest news traders need to know about the company. Source: Miro Vrlik Photography / Shutterstock.com Let’s get...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, shares of Vaxxinity (NASDAQ: VAXX ) closed higher by 18% after coming public just four days ago on Nov. 11. VAXX stock debuted at $13 per share, trading as high as $22.77 on its opening day before cooling down....

Vaxxinity (VAXX +22.1%), which had its IPO on Thursday, is up another 21% today. Its IPO was priced at $13 per share. As of 205p ET today, shares were at $16.34. Vaxxinity's latest stage candidates, both in phase 2, are UB-311 for Alzheimer's disease, and UB-612 for COVID-19. For further de...